The Apothecary Shoppe (CFP Acquisitions, Inc.), Tulsa, OK

Is The Apothecary Shoppe (CFP Acquisitions, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location.

Does The Apothecary Shoppe (CFP Acquisitions, Inc.) hold a Oklahoma pharmacy license?

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

Has The Apothecary Shoppe (CFP Acquisitions, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Mar 7, 2023), 1 state referral letter (Mar 24, 2023) and 1 FMD-145 letter (Mar 7, 2023) for The Apothecary Shoppe (CFP Acquisitions, Inc.). State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
CFP Acquisitions, Inc.; The Apothecary Shoppe
Location
Tulsa, OK
Type as FDA labels it
Not stated
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Mar 24, 2023
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
1 Form 483, 5 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as CFP Acquisitions, Inc. dba The Apothecary Shoppe, with 4 dated actions.

Document
Mar 24, 2023State referral letterState Referral Letter Issued 3/24/2023Not linked by FDA
Mar 7, 2023Warning letter close-outWarning Letter Closeout Issued 3/7/2023Not linked by FDA
Mar 7, 2023FMD-145 letterFMD-145 Letter Issued 03/07/2023Not linked by FDA
Jan 18, 2022Form 483483 Issued 01/18/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists CFP Acquisitions Inc., Tulsa, OK (FEI number 3001576820), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jan 18, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30015768201161167
Jul 11, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30015768201058647
Mar 13, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3001576820917724

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection dated Jan 18, 2022 by FDA (dates on the form not read): 5 observations

Firm on the cover
CFP Acquisitions, Inc., 6136 E. 51st St., Tulsa, OK 74135
FEI number
3001576820
Establishment type on the cover
Producer of sterile drug products
FDA district office on the cover
One Main Place 1201 Main St, Suite 7200 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Your firm released drug product in which the strength differs from that which it purports or is represented to possess.

Specifically, 3rd party testing of Lot #09082021@1 of Methylcobalamin 5000mcg/mL Injectable made on September 8, 2021 found the potency to be 89.3%. The specifications for assay for this product are <Redacted B4>. Your firm did not reject the product and instead distributed the product to customers, increasing the dose to be administered. The Formula Worksheet for this lot does not document the exact number of vials that were filled. Based on the next lot made, approximately <Redacted B4> and <Redacted B4> vials were filled. Your firm has dispensed the entire lot.

Observation 2

Your cleanrooms are outfitted with HEPA filters directly adjacent to the return vent in the ceiling.

Specifically, your ISO 7 Buffer Room and ISO 8 Ante Room are not designed with low wall air returns or returns near the floor. The air returns are in the ceiling next to the high efficiency particulate arrestance (HEPA) filter. This design does not allow for proper circulation of air and prevents effective dilution of particle-laden air by HEPA filtered air.

Add Continuation Page

Observation 3

There is a lack of routine and rigorous certification of the ISO 5 area, including smoke studies performed under dynamic conditions.

Specifically, your firm has not performed smoke studies in the ISO 5 Laminar Flow Hood (LFH) and ISO 7 Buffer Room under dynamic conditions that simulate actual working conditions since 2018.

Observation 4

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, your firm uses <Redacted B4> grade to adjust the pH of several sterile drug products, including <Redacted B4>. Furthermore, your firm did not list this in gradient on the Formula Worksheets when used. Lots that were made and dispensed /distributed include lot #s <Redacted B4> and <Redacted B4>

Add Continuation Page

Observation 5

Media fills were not performed to closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Specifically, media fills performed by your firm with each of the operators that work in the ISO 5 area do not closely simulate actual production conditions and/or cover worst case or most challenging conditions for "batch filling" (non-ophthalmic sterile drug products). In routine production, your firm fills sterile drug products into <Redacted B4> vials and batch sizes can be in excess of <Redacted B4> units.

The media fill your firm performs has the operator filling < Redacted B 4> vials <Redacted B4> fills in <Redacted B4> vial. Your firm does not include any media fills with <Redacted B4> vials.

Your firm has no documentation showing the incubation and final read results for the <Redacted B4> vials that are <Redacted B4> fill in a <Redacted B4> vial. Your firm only documents the incubation and read results for the <Redacted B4> vials that are a <Redacted B4> fill in a <Redacted B4>vial.

This is a repeat observation from the 3/3-13/15 and 6/25-07/11/2018 inspections. ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.